Rebirth of the God-level Xueba

In Liander's concept, a 10% share of US$1 million is prepared for those drugs that have passed the first clinical phase. Tomato △ novel △ net w-w-w`. x-f`q-x`s`w. com

The first clinical phase is a safety experiment, which is prepared to test whether the drug has strong side effects.

It is not difficult to pass this project. If you take a few milligrams a day, Guanyin Clay can also pass the first phase of the clinical test.

Therefore, to be able to get a drug valued at $10 million after the first clinical phase, it must be famous and promising.

Just like now, if Yang Rui or his laboratory made a certain compound and passed the first phase of the clinical trial, it would naturally be worth tens of millions of estimates.

However, Yang Rui is now empty-handed.

That is to say, he used his name to get a valuation of tens of millions of dollars.

This is 10 million U.S. dollars in 1986, and the value is still quite high. Moreover, although the biomedical industry had some bubbles in the 1980s, it cannot be compared with the Internet industry after all. There are only a few pharmaceutical companies that can come up with large sums of money. Relatively speaking, they are still conservative.

The $15 million valuation offered by Greenstone Point has even wiped out Liander's perception.

To say that pharmaceutical companies occasionally produce one or two fools. Just like real estate agents, they always have their brains drawn and hold a sign to buy a piece of bad land. However, the probability of two fools meeting at the same time is still relatively small. .

Leander looked at the manager of Greenstone Point on the left, and then at the manager of GLENSTK on the right, and he couldn't help thinking.

"1.7 million U.S. dollars, ten percent." Thorndike of Glensburgh offered another price.

Hawthorne of Greenstone Point called for 1.8 million dollars and looked at Thorndike.

Liander is familiar with the look in his eyes, and it is the look that I will withdraw when you shout loudly.

Leander's attention was placed on Thorndike's face.

Thorndike smiled triumphantly and said steadily, "US$1.85 million, ten percent."

He doesn't need to open a higher price. If Hawthorne of Greenstone Point specifies to withdraw, he has to save a little for the company.

Hawthorne's expression was a little distorted, he hesitated for several seconds, before Yang Rui was about to speak, said: "1.5 million US dollars, 8%."

At first glance, he seems to have lowered the number. However, because the proportion required is smaller, the actual valuation is higher, reaching 18.75 million U.S. dollars, although it is only 25 more than GlenSike, where Thorndike is located. The valuation of ten thousand dollars makes the latter even more entangled.

Liandel suddenly realized that the two companies were actually fighting for the right to participate.

Ten percent or eight percent of the equity is just a barrier to entry for them. What a company really spends is only more than one million U.S. dollars.

According to the standards of 86 years, more than one million US dollars is not a huge number for pharmaceutical companies. Whether it is for marketing or research investment, this is an expense of less than one month.

However, Liander did not obtain the relevant authorization from the company, which made him a little anxious.

Fortunately, Yang Rui quickly prevented the circular offer of Greenstone Point and Grundfosk, waved his hand, and said, "There is one thing that you may not know. The new medicine I made is going to be put into production in China."

"Huh? Is it made in China?" Thorndike sat upright.

Hawthorne and Leander also showed concern. However, compared to Glaszkow, Greenstone Point and Kariz Pharmaceuticals are both small and medium-sized enterprises, and their requirements for the source of medicines are not so high.

Grenschke couldn't. They are world-class multinational companies. There are still some differences in sales of medicines produced in the United States or medicines produced in China.

Of course, it is not completely impossible. For example, India has been producing various kinds of medicines for European and American pharmaceutical companies for a long time, and its chemical industry was still quite prosperous.

Regardless of what the few companies think, Yang Rui smiled and said: "I have two suggestions. One is to build a joint venture factory, so that everyone can share the benefits of the production part. If you don't want to, you can also sell as an agent, but this priority is It is lower than the partners of the joint venture factory. Only when the joint venture party gives up sales will it be given to other companies.

The white men looked at each other again.

"Professor Yang, Gaucher disease is a rare disease. There are only hundreds of thousands of patients in the world. If a joint venture is established, the profit in production will be very low." Hawthorne and his fellow white men. After a few seconds, I asked again.

"No." Yang Rui said: "We have new ideas in the enzyme substitution method. If it can be realized, it will need a larger factory to accommodate it. Therefore, the production cost and production profit will be higher than ordinary drugs. ."

"Aren't you using extracts from human placenta?" The white man behind Hawthorne suddenly asked.

"No." Yang Rui replied simply. As a rare disease, Gaucher disease has been studied in the medical field, which is one of the reasons Yang Rui chose it. If you don’t have more than 20 years of research done by the predecessors, you have to do basic research on your own movements. This is not a simple task, especially the requirements of modern medicine. It must be a quantitative result, and a plan or direction is given for granted. , Are difficult to be recognized, and quantification often means long-term experiments, not easy.

In the initial study of Gaucher's disease, enzyme substitution was the most natural way of thinking.

The structure of glucocerebrosidase in patients with Gaucher's disease has changed, and it can no longer play its due role, so add some normal glucocerebrosidase.

If the lack of enzymes is a common species, this solution can be regarded as a preliminary solution to Gaucher disease. Unfortunately, the medical experts who studied Gaucher's disease in the early stages did not find an easy source of glucocerebrosidase.

In fact, most of the self-synthesized compounds in the human body are difficult to have a stable supply. For example, the insulin needed by diabetic patients has also gone through many generations of research before they have a cheap, stable and large supply.

Glucocerebrosidase has no ready-made supply, so it can only be found from the human body and searched for. In the end, only the human placenta is considered a very reluctant source of supply. After all, it is discarded, although there are some aspects of collection and use. A lot of trouble is something that can save lives.

However, it is conceivable that the cost of glucocerebrosidase is extremely high when this extraction method is used, and there are very few Gaucher patients who can be treated.

Yang Rui’s alternative plan is to prepare glucocerebrosidase analogs in the ovarian cells of Chinese hamsters through DNA recombination technology. Although Gaucher’s disease cannot be completely cured, the biweekly plan can greatly It prolongs the life of patients and reduces pain.

For hundreds of thousands of people with Gaucher disease, as well as Gaucher disease patients with related gene mutations that will continue to appear in the future, this is the voice of heaven.

"Is there any other way to extract it without using extracts from human placenta? Is there an experimental plan?" The people at Glasgow continued to ask.

Yang Rui smiled, and he refused to talk about DNA recombination technology. He did not need to explain the drug development plan to several pharmaceutical company representatives, but his confidence and the aura of the Nobel Prize enveloped the entire laboratory. .

"In principle ~www.readwn.com~ we are willing to participate in the joint venture." It is still the people from GLENSTK who speak first.

"We have to think about it." Hawthorne's voice was a little low. Greenstone Point had not thought of a joint venture before.

Liander hesitated for a moment, but could only regretfully said: "We withdraw."

Kariz’s small only has sales and production departments, relying on purchasing a variety of formulas to make a living, they do not have the ability and ambition of multinational joint ventures.

Yang Rui expressed satisfaction. From his point of view, as long as he can tell a foreign company, the plan is effective, and then it is enough to make a plan. As for how to achieve it, that is the job of Secretary Hu and his office. child.

What Yang Rui really cares about is the technology of dna recombination. Although in more than ten or two decades, the recombinant DNA will be ruined by various laboratories, but in the time when the human genome project has not been completed or even started, the recombinant DNA is still very high-end.

It is a good thing for the ion channel laboratory to be realized and promoted in practice.

...